Analysts predict high and low EPS estimates for Pulmonx Corp (LUNG)

In the latest session, Pulmonx Corp (NASDAQ: LUNG) closed at $8.51 down -6.79% from its previous closing price of $9.13. In other words, the price has decreased by -$0.62 from its previous closing price. On the day, 286074 shares were traded.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.



For a deeper understanding of Pulmonx Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.77 and its Current Ratio is at 6.49. In the meantime, Its Debt-to-Equity ratio is 0.35 whereas as Long-Term Debt/Eq ratio is at 0.31.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on February 23, 2024, Downgraded its rating to Equal Weight and sets its target price to $14 from $16 previously.

On September 05, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $18.

Wells Fargo Upgraded its Equal Weight to Overweight on February 27, 2023, whereas the target price for the stock was revised from $10 to $15.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 22 ’24 when Rose Geoffrey Beran sold 1,184 shares for $9.36 per share. The transaction valued at 11,082 led to the insider holds 307,868 shares of the business.

French Glendon E. III sold 6,954 shares of LUNG for $63,003 on Mar 01 ’24. The PRESIDENT AND CEO now owns 1,116,758 shares after completing the transaction at $9.06 per share. On Mar 01 ’24, another insider, Lehman David Aaron, who serves as the GENERAL COUNSEL of the company, sold 4,351 shares for $9.06 each. As a result, the insider received 39,420 and left with 145,488 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LUNG now has a Market Capitalization of 328.34M and an Enterprise Value of 252.66M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.78 while its Price-to-Book (P/B) ratio in mrq is 2.77. Its current Enterprise Value per Revenue stands at 3.68 whereas that against EBITDA is -4.55.

Stock Price History:

Over the past 52 weeks, LUNG has reached a high of $14.84, while it has fallen to a 52-week low of $7.75. The 50-Day Moving Average of the stock is 11.39, while the 200-Day Moving Average is calculated to be 11.31.

Shares Statistics:

For the past three months, LUNG has traded an average of 494.87K shares per day and 630.94k over the past ten days. A total of 38.52M shares are outstanding, with a floating share count of 34.95M. Insiders hold about 9.31% of the company’s shares, while institutions hold 88.75% stake in the company. Shares short for LUNG as of Mar 15, 2024 were 1.04M with a Short Ratio of 2.11, compared to 1.26M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.70% and a Short% of Float of 3.30%.

Earnings Estimates

There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.47 for the current quarter, with a high estimate of -$0.4 and a low estimate of -$0.51, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.46, with high estimates of -$0.43 and low estimates of -$0.49.

Analysts are recommending an EPS of between -$1.78 and -$1.94 for the fiscal current year, implying an average EPS of -$1.85. EPS for the following year is -$1.57, with 6 analysts recommending between -$1.17 and -$1.81.

Revenue Estimates

A total of 6 analysts believe the company’s revenue will be $18.03M this quarter.It ranges from a high estimate of $18.8M to a low estimate of $17.5M. As of the current estimate, Pulmonx Corp’s year-ago sales were $13.49M, an estimated increase of 33.70% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $20.73M, an increase of 20.60% less than the figure of $33.70% in the same quarter last year. There is a high estimate of $21.5M for the next quarter, whereas the lowest estimate is $20.36M.

A total of 6 analysts have provided revenue estimates for LUNG’s current fiscal year. The highest revenue estimate was $83.3M, while the lowest revenue estimate was $81.1M, resulting in an average revenue estimate of $82.37M. In the same quarter a year ago, actual revenue was $68.67M, up 19.90% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $97.58M in the next fiscal year. The high estimate is $101.1M and the low estimate is $92.8M. The average revenue growth estimate for next year is up 18.50% from the average revenue estimate for this year.

Most Popular